イブジラスト
参考資料

↑  “Preferential inhibition of human phosphodiesterase 4 by ibudilast”. Life Sciences 78 (23):  2663–8. (May 2006). doi:10.1016/j.lfs.2005.10.026. PMID 16313925.
↑  “Ibudilast suppresses TNFalpha production by glial cells functioning mainly as type III phosphodiesterase inhibitor in the CNS”. Brain Research 837 (1-2):  203–12. (August 1999). doi:10.1016/s0006-8993(99)01666-2. PMID 10434004.
↑  “The inhibitory profile of Ibudilast against the human phosphodiesterase enzyme family”. European Journal of Pharmacology 538 (1-3):  39–42. (May 2006). doi:10.1016/j.ejphar.2006.02.053. PMID 16674936.
1 2  “ケタスカプセル10mg 添付文書”. www.pmda.go.jp. 2021年12月8日閲覧。
↑  “Ketas (ibudilast) Capsules 10 mg. Prescribing Information”.   Kyorin Pharmaceutical Co., Ltd.. 2016年8月3日時点のオリジナルよりアーカイブ。2016年10月3日閲覧。
1 2  “ケタス点眼液0.01％ 添付文書”. www.pmda.go.jp. 2021年12月8日閲覧。
↑  “Ketas (ibudilast) Eye Drops 0.01% Kisuri-no-Shiori (Drug Information Sheet)”.   Senju Pharmaceutical Co., Ltd.. 3 October 2016閲覧。
↑  “Cure for Meth Addiction?” (2013年4月3日). 2021年12月8日閲覧。
↑  “The effects of ibudilast, a glial activation inhibitor, on opioid withdrawal symptoms in opioid-dependent volunteers”. Addiction Biology 21 (4):  895–903. (July 2016). doi:10.1111/adb.12261. PMC 4644513. PMID 25975386. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4644513/.
↑  “Ibudilast reduces alcohol drinking in multiple animal models of alcohol dependence”. Addiction Biology 20 (1):  38–42. (January 2015). doi:10.1111/adb.12106. PMC 4017009. PMID 24215262. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4017009/.
↑  “Ibudilast: a non-selective PDE inhibitor with multiple actions on blood cells and the vascular wall”. Cardiovascular Drug Reviews 19 (3):  215–25. (Fall 2001). doi:10.1111/j.1527-3466.2001.tb00066.x. PMID 11607039.
↑  “Neuroprotective role of phosphodiesterase inhibitor ibudilast on neuronal cell death induced by activated microglia”. Neuropharmacology 46 (3):  404–11. (March 2004). doi:10.1016/j.neuropharm.2003.09.009. PMID 14975696.
↑  “Effects of ibudilast on hippocampal long-term potentiation and passive avoidance responses in rats with transient cerebral ischemia”. Pharmacological Research 45 (4):  305–11. (April 2002). doi:10.1006/phrs.2002.0949. PMID 12030794.
↑  “Ibudilast, a phosphodiesterase inhibitor, protects against white matter damage under chronic cerebral hypoperfusion in the rat”. Brain Research 992 (1):  53–9. (November 2003). doi:10.1016/j.brainres.2003.08.028. PMID 14604772.
↑  “Potentiation of ibudilast inhibition of platelet aggregation in the presence of endothelial cells”. Thrombosis Research 102 (3):  239–46. (May 2001). doi:10.1016/s0049-3848(01)00258-4. PMID 11369417.
↑  “Ibudilast, a nonselective phosphodiesterase inhibitor, regulates Th1/Th2 balance and NKT cell subset in multiple sclerosis”. Multiple Sclerosis 10 (5):  494–8. (October 2004). doi:10.1191/1352458504ms1070oa. PMID 15471363.
↑  “Ibudilast (AV-411). A new class therapeutic candidate for neuropathic pain and opioid withdrawal syndromes”. Expert Opinion on Investigational Drugs 16 (7):  935–50. (July 2007). doi:10.1517/13543784.16.7.935. PMID 17594181.
↑  “[Toll-like receptor 4: the potential therapeutic target for neuropathic pain]”. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. Acta Academiae Medicinae Sinicae 34 (2):  168–73. (April 2012). doi:10.3881/j.issn.1000-503X.2012.02.013. PMID 22776604.
↑  “Evidence that opioids may have toll-like receptor 4 and MD-2 effects”. Brain, Behavior, and Immunity 24 (1):  83–95. (January 2010). doi:10.1016/j.bbi.2009.08.004. PMC 2788078. PMID 19679181. https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2788078/.
↑  “Phosphodiesterase 4 and its inhibitors in inflammatory diseases”. Chang Gung Medical Journal 35 (3):  197–210. (2012-06-01). doi:10.4103/2319-4170.106152. PMID 22735051.
↑  “Mechanism of allodynia evoked by intrathecal morphine-3-glucuronide in mice”. International Review of Neurobiology 85:  207–19. (2009-01-01). doi:10.1016/S0074-7742(09)85016-2. PMID 19607972.